These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12921504)

  • 21. Role of anagrelide in the treatment of thrombocytosis.
    Brooks WG; Stanley DD; Goode JV
    Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
    Internullo M; Giannelli V; Sardo L; Antonaglia C; Villani T; Angelici E; Palange P
    Eur Rev Med Pharmacol Sci; 2014; 18(2):190-3. PubMed ID: 24488907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD
    Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
    Wirth K; Schoepf E; Mertelsmann R; Lindemann A
    Br J Dermatol; 1998 Mar; 138(3):533-5. PubMed ID: 9580816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypersensitivity pneumonitis associated with the use of temozolomide.
    Koschel D; Handzhiev S; Leucht V; Holotiuk O; Fisseler-Eckhoff A; Höffken G
    Eur Respir J; 2009 Apr; 33(4):931-4. PubMed ID: 19336595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia.
    Jackson GH; Wallis J; Ledingham J; Lennard A; Proctor SJ
    Cancer Chemother Pharmacol; 1990; 27(2):168-9. PubMed ID: 2249336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
    Janssen JJ; Ossenkoppele GJ
    Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1517-20. PubMed ID: 12924084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Dingli D; Tefferi A
    Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia.
    Singh P
    J Pharm Pract; 2018 Apr; 31(2):230-233. PubMed ID: 28343445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrotic Lung Toxicity Induced by Hydroxycarbamide.
    Bargagli E; Palazzi M; Perri F; Torricelli E; Rosi E; Bindi A; Pistolesi M; Voltolini L
    In Vivo; 2017; 31(6):1221-1223. PubMed ID: 29102950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anagrelide in primary thrombocythemia].
    Knutsen H; Hysing J
    Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
    Golub R; Adams J; Dave S; Bennett CL
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):28-32. PubMed ID: 12096355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
    Hong Y; Erusalimsky JD
    Platelets; 2002 Nov; 13(7):381-6. PubMed ID: 12487784
    [No Abstract]   [Full Text] [Related]  

  • 37. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
    Penninga E; Jensen BA; Hansen PB; Clausen NT; Mourits-Andersen T; Nielsen OJ; Hasselbalch HC
    Clin Lab Haematol; 2004 Oct; 26(5):335-40. PubMed ID: 15485463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
    Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Ruiz-Reyes G; Chernoff SG
    Mayo Clin Proc; 1998 Nov; 73(11):1125. PubMed ID: 9818051
    [No Abstract]   [Full Text] [Related]  

  • 39. Platelet Anti-Aggregator Drowns the Heart.
    Siddiqui MU; Siddiqui MD; Hameed S; Naeem Z; Siddiqui M
    S D Med; 2021 Nov; 74(11):502-505. PubMed ID: 35008135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia.
    Kallel F; Kassar O; Maaloul I; Charfi M; Ksouda K; Elloumi M
    J Oncol Pharm Pract; 2021 Oct; 27(7):1762-1765. PubMed ID: 33375903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.